IDO1 and cancer: Therefore, the high IDO1 expression is not a single indicator to decide whether to choose IDO1 inhibitors, and the IDO1 activity assessment may also need multiple factors, including the concentrations of Trp and Kyn as well as the Kyn/Trp ratio in human cancers.